Fondazione Ricerca e Innovazione Cardiovascolare Completes Enrollment in TRANSFORM II RCT, A landmark study comparing MagicTouch SCB vs DES in Native Coronary Vessels
TRANSFORM II (Sirolimus-Coated Balloon Versus Drug-Eluting Stent in Native Coronary Vessels) is an investigator-driven trial sponsored by Fondazione Ricerca e Innovazione Cardiovascolare in Milano, Italy, and has now achieved its target enrollment of >1,820 patients. The final patient was enrolled on 6 th June 2025, marking a major milestone for the trial. Led by Study Chairman Prof. Bernardo Cortese (University Hospitals Harrington Heart & Vascular Institute, Cleveland, USA) and a distinguished steering committee, TRANSFORM II is one of the largest global randomized controlled trials evaluating drug-coated balloon and has enrolled patients from 52 centers across Europe, Asia and South America. Key features of the TRANSFORM II trial include:
Comparative Arms: MagicTouch SCB vs. Everolimus-Eluting Stent (EES)
Patient Population: 1,832 patients with de-novo lesions in coronary arteries (vessel diameter >2.0 mm to ≤3.5 mm; lesion length ≤50 mm)
Primary Endpoint: Target Lesion Failure at 12 months, non-inferiority design
Follow-Up: Patients will be monitored for up to 60 months (5 years)
Sub-Study: Optical Coherence Tomography (OCT) imaging in 70 patients at 9 months to assess angiographic outcomes
Prof. Bernardo Cortese, Study Chairman of TRANSFORM II, commented: "After 3 and a half years we were able to complete the enrollment in TRANSFORM II trial, a study that involved 52 centers across 3 continents, and this is amazing. The effort put by our Team in Fondazione RIC and each Investigator of the study led to a quite fast enrollment in such a big, ambitious study. Our goal is to advance the adoption of DCB in the coronary space, testing this sirolimus DCB with the most studied and used DES, in a daily patient population. Along with the guidance of the recently published DCB ARC guidelines, we are paving the route for the modern angioplasty era!".
Coronary vessels of this size (which account for roughly 80% of patients undergoing percutaneous coronary interventions) present unique treatment challenges. Currently, interventional cardiologists must often choose a permanent implant namely a drug-eluting stent — effectively "caging" a small vessel — which may compromise long-term outcomes. The head-to-head comparison of MagicTouch SCB against a current standard of care (the EES family of drug-eluting stents) in TRANSFORM II is poised to provide critical evidence for an alternative approach. This trial has the potential to reshape treatment practices by establishing drug-coated balloons as the next viable option for patients with coronary artery disease.
Drug-coated balloon technology has long been viewed as a promising solution for small, de-novo coronary lesions, and sirolimus is a viable alternative to the first generation of DCB eluting paclitaxel. Data from this large-scale RCT are expected to support a paradigm shift towards broader use of drug-coated balloons. Implanting a drug-eluting stent in a tiny artery is far from ideal for both patients and physicians, so a rigorous study validating the use of SCB was needed. TRANSFORM II is set to fulfill that need, with initial 12-month outcomes anticipated to shed light on the long-term benefits of avoiding permanent implants in coronary vessels.
Dr. Manish Doshi, Founder & Managing Director of Concept Medical Group, commented: "The completion of patient enrollment in TRANSFORM II is a significant milestone in our mission to bring innovative drug-delivery technologies to the forefront of interventional cardiology. We are proud to scientifically support one of the largest global randomized trials evaluating sirolimus-coated balloon technology. This achievement reflects our commitment to clinical excellence, scientific rigor, and ultimately, better outcomes for patients around the world."
About MagicTouch SCB
The MagicTouch SCB, developed by Concept Medical Inc., utilizes proprietary Nanoluté technology to deliver sub-micron particles of sirolimus encapsulated in a biocompatible carrier, ensuring deep penetration into the vessel wall. The device has received CE Mark approval in Europe alongwith Breakthrough Device Designation & IDE Approval from the U.S. FDA for the treatment of small coronary vessels and in-stent restenosis with ongoing clinical trials.
About Concept Medical Inc.
Concept Medical Inc., headquartered in Tampa, Florida, has a global presence and is dedicated to enhancing patient care through cutting-edge research and development of drug-delivery technologies. Its proprietary platforms are designed to deliver pharmaceutical agents across vascular luminal surfaces with unparalleled precision. Concept Medical is the developer of the MagicTouch family of Sirolimus-Coated Balloons (SCB) – the world's first and most utilized SCB technology – well recognized for its versatility and efficacy in treating coronary and peripheral artery disease. The revolutionary MagicTouch and Abluminus product lines have been used to treat over a million patients globally, setting a new standard for vascular therapy.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
an hour ago
- Cision Canada
No More Juggling a Dozen Apps -- Prevention Now Lives in One Immersive, AI-Powered Experience
Ginkgo Active 4.0 Unlocks Holistic Health Guidance, Making Prevention as Easy as a Daily Check-in VANCOUVER, BC, Aug. 18, 2025 /CNW/ - Ginkgo Active, the world's first Virtual Proactive Health Centre, has launched its most transformative update yet — combining science-based training with interactive habit check-ins to deliver a truly holistic, lifelong prevention experience. In this release, Ginkgo Active goes beyond physical training, integrating the biopsychosocial model into an intelligent, unified platform. Members will now explore their own private health island, where every new assessment unlocks fresh spaces — from the Kitchen for healthy eating, to the Spa for mental wellness, to the Tennis Court for activity and movement literacy. Each space comes with 14-day Healthy Habit Challenges that guide users toward better sleep, nutrition, activity, and social connection. "Prevention doesn't happen with one app or one visit — it's a lifelong journey," said Maggie Deng, Founder & CEO of Ginkgo Health. "This new version brings all the elements of a proactive health plan together in one place, powered by AI, so people can turn knowledge into daily actions without the overwhelm." Why It Matters Full-spectrum prevention: Tackles physical, mental, and social health together — no more scattered apps or siloed advice. AI-powered personalization: Transforms over 570 personal health variables into safe, effective daily guidance. Lifelong engagement: Every new challenge and unlocked space makes healthy living an evolving, rewarding experience. "We've built a fully integrated data and reasoning system that synchronizes traditionally siloed health insights — from sleep and nutrition to activity and social engagement — into a single, adaptive model," said Ruoshi Li, Co-founder & CTO of Ginkgo Health. "Our AI continuously processes vast sets of validated health rules and lifestyle guidelines, then dynamically generates individualized, actionable recommendations at a scale no human expert could match in real time." With this update, Ginkgo Active cements its position as the only platform that delivers precise prevention for decline and chronic conditions in an engaging, scalable, and globally accessible format. Availability: The new Ginkgo Active update is available immediately for all members via App Store and for group enrollments through healthcare payers, employers, and wellness providers. About Ginkgo Active: Ginkgo Active is the world's first Virtual Proactive Health Centre, designed to help people live longer, healthier, more independent lives. Built on evidence-based guidelines and powered by AI, it delivers daily personalized training plans, holistic habit challenges, and continuous progress tracking — all in a single, immersive platform.
Cision Canada
2 hours ago
- Cision Canada
Newfoundland Power Announces Closing of $120 Million Bond Issue
ST JOHN'S, NL, Aug. 18, 2025 /CNW/ - Newfoundland Power Inc. announced today the closing of $120 million, 4.913 per cent First Mortgage Sinking Fund Bonds, due August 18, 2055. The net proceeds from the private placement will be used by the Company to repay credit facility borrowings, primarily incurred to finance the Company's capital expenditure program, and for general corporate purposes. About Newfoundland Power Newfoundland Power is the primary distributor of electricity on the island portion of Newfoundland and Labrador, purchasing 93% of its energy from Newfoundland and Labrador Hydro. With approximately 278,000 customers across the most expansive service territory in Atlantic Canada, Newfoundland Power is committed to safety, the highest level of customer service and the delivery of reliable, least-cost electricity. SOURCE Newfoundland Power Inc.
Cision Canada
3 hours ago
- Cision Canada
Premier Ford announces $1.6 billion funding boost for municipal infrastructure at 2025 AMO Conference
OTTAWA, ON, /CNW/ - Today at the 2025 Association of Municipalities of Ontario (AMO) Conference in Ottawa, Premier Doug Ford announced an additional $1.6 billion for the Municipal Housing Infrastructure Program. AMO welcomes the boost in funding for core infrastructure projects, like roads and water systems, that support communities and growth. AMO has called for infrastructure investments to support growth, build more homes, and provide economic stimulus in the face of the trade dispute with the United States and global economic uncertainty. "Investments in municipal infrastructure have consistently proven to be the best way to protect local, provincial and national economies," said Robin Jones, AMO President. "These investments will not just help to build homes, they will provide thousands of jobs in communities across the province and lay the foundation for long-term productivity. We commend Premier Ford for these important investments." Municipalities are committed to supporting the Province's ambitious growth agenda and doing all they can to help achieve it. Despite rising construction costs, municipalities are increasing infrastructure investment this year to support more housing and economic development. Municipal applications to existing infrastructure programs have been robust, demonstrating no shortage of shovel ready projects that can make a meaningful impact province-wide. AMO is calling for a stimulus investment of $3.45 billion annually over five years from both provincial and federal sources for municipal infrastructure and social housing. These investments would help to mitigate the negative impacts on Ontario's economy and help save jobs across the province, by: Protecting 14,000 jobs that would be lost in 2026 alone, including almost 5,000 in the construction sector, and Reducing Ontario's GDP contraction by 28 per cent and adding $17.6 billion back into the Ontario economy over the next five years. Stimulus investments would lead to ongoing productivity gains totaling as much as $6 billion in 2029 alone. The provincial announcements today are a considerable contribution to this stimulus investment. "It will take investment from all governments to address the need for core infrastructure that underpins our economy," said Robin Jones, AMO President. "Investing in municipal infrastructure now will pay off in long-term productivity." The annual AMO conference is an important opportunity for municipal and provincial leaders from across Ontario to come together, address shared challenges and make Ontario's communities, and the province as a whole, more successful. AMO launched an Indigenous Relations Action Plan at the Conference, working with partners to strengthen municipal-Indigenous relationships. Tomorrow, delegates will turn their attention to a full day of sessions on pressing municipal priorities. The plenary program will include The Honourable Rob Flack, Minister of Municipal Affairs and Housing, and the Ministers' Forum, a Q&A opportunity with Cabinet ministers. Concurrent sessions will explore housing and land-use planning, municipal finance and economic development, Indigenous partnerships, and AI in municipal services. Program information is available at or on the AMO Conference app for iPhone and Android. The Conference hashtag is #AMO2025. AMO works to make municipal governments stronger and more effective. AMO brings together Ontario's 444 municipalities to achieve shared goals and meet common challenges. Follow AMO on LinkedIn, X: @AMOPolicy, and Instagram: @amopolicy. Quick facts Ontario municipalities own and operate almost $1 trillion worth of public infrastructure. Over the next 10 years, municipalities are planning for more than $250 billion in capital expenditures – with around $100 billion related to growth. Municipalities are planning $51 billion in capital spending between 2025 and 2027. This represents more than 27,000 infrastructure projects and more than 19,000 new social housing units. With tariffs increasing project costs, municipal infrastructure projects already in progress need support to stay on track. Municipalities invest $68 billion annually in the provincial and local economies. This spending includes about $26 billion annually on construction and $22 billion procuring other related goods and services.
